This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Pacific Meso Center Celebrates Grand Opening Of First Free-Standing International Mesothelioma Research Laboratory On February 13

LOS ANGELES, Feb. 12, 2013 /PRNewswire/ -- On Wednesday, February 13 th the Pacific Meso Center (PMC) will celebrate the grand opening of a new state-of-the-art laboratory dedicated solely to the discovery of new treatments and prevention of malignant pleural mesothelioma (MPM), a cancer of the chest lining (pleura) caused by asbestos exposure.

As the first of its kind in the world, the PMC Research Laboratory is headed by a distinguished team of physicians and scientists focused solely on mesothelioma research in a collaborative effort that is independent of the limitations often imposed by academic and private medical institutions. The team includes one of the foremost experts in the field of mesothelioma research and treatment, Robert B. Cameron, M.D., who serves as PMC's scientific advisor. Dr. Cameron is a cardiothoracic surgeon and surgical oncologist, the director of the UCLA Comprehensive Mesothelioma Program at the David Geffen School of Medicine at UCLA, Chief of Thoracic Surgery at the West Los Angeles Veterans' Administration Medical Center, and a long-time proponent of lung-sparing surgery for malignant pleural mesothelioma.  He organizes the Annual International Symposia on Lung-Sparing Therapies for Malignant Pleural Mesothelioma, which is held each spring in Santa Monica, CA.

Scientists at PMC are developing innovative treatments based on the body's immune system which are capable of eradicating tumor cells. Additional projects include cryotherapy, (freezing cancer cells); mesothelioma breath screening, tissue banking, and medical informatics.

The Grand Opening will be held on Wednesday, February 13 th from 1:00 to 7:00 p.m. at the PMC Research Laboratory, located at 10780 Santa Monica Blvd. in Los Angeles.

"We are very excited about the potential for new scientific discoveries aimed at the prevention and treatment of MPM," says Clare Cameron, executive director. "I believe our new dedicated facility, spearheaded by a remarkable team of scientists, will lead to novel approaches that will eventually eradicate this virulent form of cancer." Many of the latest discoveries will be presented at The 3 rd International Symposium on Lung-Sparing Therapies, scheduled for Saturday, May 18 th, 2013 in Santa Monica, California.

About The Pacific Meso Center:

The Pacific Meso Center (PMC) is a division of the Pacific Heart, Lung & Blood Institute, a 501(c)(3) non-profit medical research institute established in 2002 which is focused on the treatment and prevention of malignant pleural mesothelioma (MPM).  The exploration of innovative ideas forms the foundation of PMC's unique research program and provides the promise of future treatment breakthroughs.  PMC is dedicated to educating the public on asbestos-related diseases and informing them of their best treatment options.  PMC also connects newly diagnosed patients with patients that have been through treatment and provides assistance and emotional support.

For further information please contact:

Clare Cameron 310-478-4678   ccameron@phlbi.org.    www.pacificmesocenter.org   or www.phlbi.org

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE The Pacific Meso Center

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs